LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. As an inducement to join the company, Zergebel received an equity award of options to purchase 75,000 shares at an exercise price of $32.95 per share, vesting over 4 years. The company continues advancing its lead candidate LB-102, a novel antipsychotic in Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression.